Clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses, but is underutilized partly due to clinician unfamiliarity with monitoring principles and side-effect management. This Handbook provides clinically focussed approaches and logic for clinicians to manage clozapine-treated patients.
Clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses, but is underutilized partly due to clinician unfamiliarity with monitoring principles and side-effect management. This Handbook provides clinically focussed approaches and logic for clinicians to manage clozapine-treated patients.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Jonathan M. Meyer is currently a Clinical Professor of Psychiatry at the University of California, San Diego and a Psychopharmacology Consultant to the California Department of State Hospitals. Dr Meyer is an internationally recognised speaker on psychopharmacology and the treatment of severe mental illness, and is Distinguished Fellow of the American Psychiatric Association.
Inhaltsangabe
Preface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile metabolism kinetics drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever myocarditis interstitial nephritis DRESS serositis and cardiomyopathy; 10. Eosinophilia leukocytosis thrombocytopenia thrombocytosis anemia hepatic function abnormalities; 11. Managing enuresis and incontinence priapism venous thromboembolism neuroleptic malignant syndrome tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia psychogenic polydipsia treatment intolerant schizophrenia suicidality violence mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients elderly patients patients with intellectual disability pregnancy and risk for major congenital malformation lactation overdose postmortem redistribution; Index.
Preface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile metabolism kinetics drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever myocarditis interstitial nephritis DRESS serositis and cardiomyopathy; 10. Eosinophilia leukocytosis thrombocytopenia thrombocytosis anemia hepatic function abnormalities; 11. Managing enuresis and incontinence priapism venous thromboembolism neuroleptic malignant syndrome tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia psychogenic polydipsia treatment intolerant schizophrenia suicidality violence mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients elderly patients patients with intellectual disability pregnancy and risk for major congenital malformation lactation overdose postmortem redistribution; Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der Steintor 70. V V GmbH (zukünftig firmierend: buecher.de internetstores GmbH)
Geschäftsführung: Monica Sawhney | Roland Kölbl
Sitz der Gesellschaft: Hannover
Amtsgericht Hannover HRB 227001
Steuernummer: 321/neu
